Lachlan Hanbury Brown, an analyst from William Blair, has initiated a new Buy rating on Kalaris Therapeutics (KLRS).
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors that highlight the potential of Kalaris Therapeutics in the retinal vascular disease market. The company is developing TH103, an innovative anti-VEGF fusion protein, which shows promise in offering greater potency and ocular retention compared to existing treatments like aflibercept. This advancement could lead to better patient compliance and outcomes, addressing a significant issue with current therapies that require frequent injections.
Furthermore, the global anti-VEGF market is substantial and growing, driven by an aging population. Kalaris’s focus on neovascular age-related macular degeneration (nAMD) with the potential to expand into other retinal disorders positions it well within this lucrative market. The ongoing Phase I study of TH103 and its encouraging preclinical results suggest that Kalaris could capture a significant share of this expanding market, justifying the Buy rating.